+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Verona Pharma plc - logo

Verona Pharma is a biopharmaceutical company that aims to improve the lives of those suffering from respiratory diseases by innovating therapeutic products. It was founded in 2005 in London, England. There proprietary lead candidate, RPL554 has opened a door to a whole new generation of drugs as it combines bronchodilator and an anti-inflammatory agent in a single compound. It has the potential to provide relief for the many patients suffering from respiratory conditions such as chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and possibly asthma. Verona Pharma is listed on the NASDAQ global market and is supported by investors from U.S, U.K and Europe.

Asthma Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Asthma Therapeutics - Global Strategic Business Report

  • Report
  • April 2024
  • 194 Pages
  • Global
From
From
From
Asthma & COPD Therapies Market Report 2023-2033 - Product Thumbnail Image

Asthma & COPD Therapies Market Report 2023-2033

  • Report
  • January 2023
  • 248 Pages
  • Global
From
From
From
From
From
From
Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2024 - Product Thumbnail Image

Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 220 Pages
  • Global
From
Cystic Fibrosis Market - Forecasts from 2024 to 2029 - Product Thumbnail Image

Cystic Fibrosis Market - Forecasts from 2024 to 2029

  • Report
  • January 2024
  • 145 Pages
  • Global
From
Loading Indicator